San Carlos, CA, August 14, 2012 --(PR.com
)-- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration with Stiefel, a GSK Company, will be presented at the 17th International Inflammation Research Association Conference in Lake George, NY, September 9-13th, 2012. Dr. Betty Hussey, Director, Clinical Pharmacology of GSK will present a poster entitled “Physiological model to investigate and prioritize targets for psoriasis.”
The presentation will describe the development and use of a custom-designed Psoriasis PhysioMap® which provided information and methodology to enable key decisions in early development target prioritization. The map was built using literature data and then critically reviewed by R&D scientists and disease experts. The presentation will show how the map was used to evaluate the roles of drug targets in disease pathways, their potential interactions, and their relative contributions to efficacy potential. This process has informed the selection and prioritization of drug development targets, and it set the stage for development of a quantitative PhysioPD model that will further elucidate and prioritize target potential.
"We are pleased to share the initial results from our ongoing collaboration with GSK,” said Dr. Rebecca Baillie, Chief Scientist, PhysioPD at Rosa. “The results of this collaboration show the business value and scientific usefulness of developing a Psoriasis PhysioMap. The PhysioMap development process was critical for establishing a common understanding of the key data and material uncertainties relevant to psoriasis and providing a framework to facilitate cross-functional communication within GSK.”
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.